Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E110.16 EPS (ttm)3.49 Insider Own0.90% Shs Outstand101.07M Perf Week14.85%
Market Cap38.86B Forward P/E31.08 EPS next Y12.37 Insider Trans-3.28% Shs Float74.40M Perf Month7.63%
Income396.30M PEG5.56 EPS next Q2.57 Inst Own75.00% Short Float5.06% Perf Quarter26.28%
Sales2.50B P/S15.55 EPS this Y-43.60% Inst Trans-0.23% Short Ratio4.72 Perf Half Y31.02%
Book/sh23.60 P/B16.29 EPS next Y22.18% ROA12.90% Target Price378.70 Perf Year26.26%
Cash/sh8.08 P/C47.57 EPS next 5Y19.82% ROE19.30% 52W Range257.69 - 384.85 Perf YTD39.68%
Dividend- P/FCF75.57 EPS past 5Y42.20% ROI19.20% 52W High2.90% Beta0.88
Dividend %- Quick Ratio5.20 Sales past 5Y54.60% Gross Margin88.20% 52W Low53.67% ATR12.10
Employees2469 Current Ratio5.50 Sales Q/Q45.50% Oper. Margin34.30% RSI (14)68.54 Volatility3.87% 3.09%
OptionableYes Debt/Eq0.22 EPS Q/Q3.80% Profit Margin15.90% Rel Volume1.01 Prev Close384.46
ShortableYes LT Debt/Eq0.22 EarningsNov 04 BMO Payout0.00% Avg Volume796.63K Price396.00
Recom2.00 SMA2011.41% SMA5012.15% SMA20024.71% Volume504,172 Change3.00%
02-Sep-14Reiterated Brean Capital Buy $380 → $390
06-Aug-14Reiterated RBC Capital Mkts Outperform $349 → $373
21-Jul-14Initiated Argus Buy $375
16-Apr-14Initiated Canaccord Genuity Buy $350
13-Feb-14Downgrade Oppenheimer Outperform → Perform $310 → $325
30-Sep-13Reiterated Oppenheimer Outperform $300 → $310
22-Aug-13Initiated Oppenheimer Outperform $300
17-May-13Initiated UBS Neutral $290
06-May-13Reiterated RBC Capital Mkts Outperform $270 → $286
06-May-13Reiterated Barclays Overweight $275 → $305
02-May-13Reiterated Barclays Overweight $194 → $275
28-Feb-13Initiated Barclays Overweight $194
21-Dec-12Reiterated RBC Capital Mkts Outperform $171 → $190
14-Feb-12Reiterated RBC Capital Mkts Outperform $83 → $130
10-Jan-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
05-Dec-11Reiterated Brean Murray Buy $78 → $67
28-Jul-11Upgrade RBC Capital Mkts Sector Perform → Outperform $70 → $70
09-May-11Reiterated Needham Buy $49 → $60
29-Apr-11Reiterated Barclays Capital Overweight $64 → $72
29-Apr-11Downgrade RBC Capital Mkts Outperform → Sector Perform $70 → $70
23-Oct-14 07:10AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Regeneron, Pharmacyclics and Repros Therapeutics Zacks
22-Oct-14 05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
10:18AM  Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? Zacks
21-Oct-14 07:56PM  Biogen Leads 5 Top Biotech Stocks As Earnings Loom at Investor's Business Daily
05:42PM  The Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
20-Oct-14 06:47PM  Three Big Cap Leaders Remain In Buy Range at Investor's Business Daily
04:45PM  Sanofi and Regeneron Dose Patients in Dupilumab Study Zacks
04:10PM  Amgen Sues Sanofi and Regeneron over PCSK9 Candidate Zacks
01:17PM  3 Drugs Stocks Dragging The Industry Down at TheStreet
07:00AM  Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis PR Newswire
04:24AM  Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% Zacks
01:18AM  Sanofi, Regeneron start Phase 3 trial of dupilumab in eczema Reuters
17-Oct-14 05:27PM  Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs +8.49%
03:14PM  4 Big Stocks on Traders' Radars at TheStreet
01:18PM  Midday movers: Aeropostale, Netflix, Textron & more at CNBC
12:53PM  [$$] Amgen Files Patent Infringement Suit at The Wall Street Journal
11:48AM  Two Tribes Go to War: Amgen Sues Regeneron for Patent Infringement at Barrons.com
11:46AM  Cramer: Regeneron's Head-to-Head Results 'Very Positive' at TheStreet
11:27AM  Regeneron Eye Drug Beats Rivals While Amgen Sues at Investor's Business Daily
10:58AM  Stocks Power Higher At Open; Regeneron Vaults On Eylea Trial at Investor's Business Daily
09:55AM  [video] Positive for Regeneron: Cramer at CNBC
08:39AM  Regeneron's Eylea works better vs Avastin and Lucentis in study Reuters
07:00AM  EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study PR Newswire
06:00AM  'Mad Money' Lightning Round: Stay the Course With Facebook at TheStreet
16-Oct-14 07:41PM  Cramer Remix: Here's why the market bounced at CNBC
07:24PM  Lightning Round: Facebook, Regeneron & More at CNBC
06:00PM  Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 Zacks
02:00PM  Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year PR Newswire
08:30AM  Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments PR Newswire
08:02AM  LinkedIn, YY Among 5 Stocks With Top Fundamentals at Investor's Business Daily
15-Oct-14 04:01PM  Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014 PR Newswire
13-Oct-14 06:38PM  Apple, McKesson Among Big Caps In Trading Range at Investor's Business Daily
04:19PM  Celgene's Otezla Encourages in Plaque Psoriasis at EADV Zacks
10-Oct-14 01:03PM  GSK, REGN And SHPG, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
09-Oct-14 08:31AM  The Zacks Analyst Blog Highlights: Sunesis Pharmaceuticals, Chimerix, Regeneron and Incyte Zacks
08-Oct-14 05:10PM  Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo Zacks
10:20AM  Amgen's Data on Evolocumab Published in The Lancet Zacks
07:14AM  Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update Zacks
07-Oct-14 03:30PM  Regeneron's Eye Drug Eylea Wins Another FDA Approval Zacks
06-Oct-14 04:58PM  EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) PR Newswire
02-Oct-14 03:33PM  Cholesterol Drugs Haunted By Ghosts Of Past, Present, And Future at Forbes
01-Oct-14 07:52PM  Alibaba Among 5 Stocks With Superior Long-Term Growth at Investor's Business Daily
05:00PM  Why October could be bad for biotech Talking Numbers
30-Sep-14 03:04PM  Stocks Move To Session Lows; Regeneron Rises On Drug Data at Investor's Business Daily
01:31PM  Q4 momentum CNBC
01:31PM  [video] Q4 momentum at CNBC
11:56AM  Regeneron, Sanofi say sinusitis drug met goals AP
11:52AM  Jim Cramer's Stop Trading: Regeneron Investors Should Not Freak Out at TheStreet
09:55AM  Cramer's Stop Trading: REGN & DWA CNBC
09:55AM  [video] Cramer's Stop Trading: REGN & DWA at CNBC
02:48AM  Sanofi-Regeneron drug has positive trial results in chronic sinusitis Reuters
01:17AM  Sanofi posts positive results for drug in chronic sinusitis Reuters
01:00AM  Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps PR Newswire
29-Sep-14 06:32PM  Large-Cap Tech, Biotech Names Hang Tough In Shaky Market at Investor's Business Daily
06:32PM  Biotech Stocks Rebound On Strong Earnings, New Drugs at Investor's Business Daily
25-Sep-14 05:17PM  Biotech selloff: What to buy CNBC
05:17PM  [video] Biotech selloff: What to buy at CNBC
02:19PM  4 picks in biotech Yahoo Finance
07:31AM  The Zacks Analyst Blog Highlights: Auxilium Pharmaceuticals, QLT, Endo International, Gilead and Regeneron Zacks
24-Sep-14 08:24PM  Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market at TheStreet
06:15PM  Cramer's favorite large cap biotech plays CNBC
06:15PM  [video] Cramer's favorite large cap biotech plays at CNBC
01:27PM  Acorda To Buy Civitas, Gains Parkinson's Disease Drug at Investor's Business Daily
10:06AM  Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA Zacks
23-Sep-14 04:05PM  Anacor's Kerydin Launched in the US for Onychomycosis Zacks
03:45PM  Bayer/Regeneron Successfully Expand Eylea Label in Japan Zacks
22-Sep-14 02:30AM  Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan PR Newswire
18-Sep-14 08:23AM  The Zacks Analyst Blog Highlights: Google, Facebook, Apple, Microsoft and Regeneron Pharmaceuticals Zacks
17-Sep-14 03:30PM  Regeneron Gets Breakthrough Therapy Status for Eylea Zacks
16-Sep-14 12:12PM  Stocks Erase Modest Gains; Netflix Gaps Below 50-Day Line at Investor's Business Daily
07:00AM  EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema PR Newswire
15-Sep-14 05:06PM  Biotech still place to be: Pro CNBC
05:06PM  [video] Biotech still place to be: Pro at CNBC
14-Sep-14 07:01PM  Costly eye drug and far cheaper alternative have similar side effects -study Reuters
11-Sep-14 02:46PM  Stocks Show Modest Losses; Biotechs Pressured Again at Investor's Business Daily
10:02AM  Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs at TheStreet
10-Sep-14 06:09PM  Like Apple, these firms satisfy unmet need: Cramer at CNBC
02:53PM  Stocks Hold Modest Gains; FleetCor Reverses Higher at Investor's Business Daily
01:25PM  Stocks Turn Higher After Soft Start; U.S. Silica Jumps at Investor's Business Daily
08-Sep-14 03:45PM  Bayer/Regeneron Looking for Eylea Label Expansion in Japan Zacks
05-Sep-14 06:33PM  Jim Cramer's fantasy stock portfolio at CNBC
06:00AM  Jim Cramer's Top Stock Picks: MMM TSLA NFLX REGN DECK at TheStreet
04-Sep-14 08:00PM  [video] Regeneron Rises, Norwegian Cruises and CVS Health Quits the Habit at TheStreet
07:45PM  Jim Cramer's 'Mad Money' Recap: Stocks Are the Rational Choice at TheStreet
06:25PM  Cramer: Football lovers make good stock pickers? at CNBC
06:25PM  [video] Cramer's WR stock pick: TSLA, NFLX, REGN at CNBC
05:00PM  Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Zacks
11:01AM  Celgene: Good Data But What About the Patent Challenges? at Barrons.com
08:32AM  The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and Aegerion Zacks
03:00AM  Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion PR Newswire
03-Sep-14 10:32AM  Sanofi: First Heart Disease, Now Dengue Fever at Barrons.com
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
06:26AM  [$$] Regeneron Shares Seen Approaching $400 at Barrons.com
02-Sep-14 06:07PM  Cramer: Twitter and other 'irresistible' stocks at CNBC
06:04PM  Novartis, Regeneron Shares Advance To New Highs On Updated Drug News Investor's Business Daily
04:19PM  Why Jim Cramer Likes Regeneron (REGN) Stock Over Sanofi (SNY) at TheStreet
03:44PM  [video] The cholesterol race at CNBC
03:30PM  Regeneron/Sanofi Presents Encouraging Alirocumab Data Zacks
03:04PM  [video] Jim Cramer Says Regeneron is a Better Way to Play it Than Sanofi at TheStreet
01:34PM  [video] Biotech's $10 billion opportunity at CNBC
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM
VAGELOS P ROYChairman of the BoardFeb 27Option Exercise12.7070,879899,952140,839Mar 03 09:10 AM
BROWN MICHAEL SDirectorFeb 27Sale335.001,000335,00014,662Feb 27 04:30 PM
BROWN MICHAEL SDirectorFeb 26Option Exercise57.111,00057,11015,662Feb 27 04:30 PM
GOLDSTEIN JOSEPH LDirectorFeb 25Sale338.861,000338,8600Feb 25 05:48 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 25Sale339.5511,8714,030,82363,102Feb 26 04:57 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 24Option Exercise64.9030,2271,961,74685,365Feb 26 04:57 PM
GILMAN ALFRED GDirectorFeb 21Option Exercise18.615,00093,0505,000Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Option Exercise15.8015,000237,000117,772Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Sale339.0015,0005,085,000112,772Feb 24 04:12 PM
GILMAN ALFRED GDirectorFeb 21Sale340.005,0001,700,0000Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 21Sale336.5121,2587,153,60863,102Feb 24 04:11 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 20Option Exercise47.7950,6522,420,80593,102Feb 24 04:11 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 20Option Exercise21.253,00063,7503,000Feb 21 04:43 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale326.991,000326,9891,000Feb 21 04:44 PM
Terifay Robert JSVP CommercialFeb 18Sale332.6812,8654,279,89320,029Feb 19 04:10 PM
Aberman Michael SVP Strategy and Investor RelatFeb 18Sale331.423,6481,209,03615,600Feb 19 04:12 PM
Aberman Michael SVP Strategy and Investor RelatFeb 14Option Exercise30.637,500229,72523,100Feb 19 04:12 PM
Terifay Robert JSVP CommercialFeb 14Option Exercise21.2527,795590,64447,824Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Option Exercise9.1715,000137,550127,772Feb 19 04:11 PM
SING GEORGE LDirectorFeb 14Sale324.0015,0004,860,000112,772Feb 19 04:11 PM
STAHL NEILSVP Research and Development SFeb 13Sale318.8222,6127,209,13624,391Feb 13 06:32 PM
STAHL NEILSVP Research and Development SFeb 12Option Exercise20.0654,5481,094,40664,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Option Exercise89.4515,0001,341,75015,000Feb 13 07:38 PM
SHOOTER ERIC MDirectorFeb 12Sale320.5215,0004,807,8690Feb 13 07:38 PM
GOLDSTEIN JOSEPH LDirectorFeb 12Sale320.621,000320,6202,000Feb 13 04:06 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 12Sale320.3388,98728,504,9851,068,343Feb 13 04:03 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 11Option Exercise9.49189,4631,798,0041,257,806Feb 13 04:03 PM
GILMAN ALFRED GDirectorFeb 11Option Exercise18.615,00093,0505,000Feb 12 04:17 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Option Exercise30.635,819178,2365,819Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Sale320.005,0001,600,0000Feb 12 04:17 PM
VAGELOS P ROYChairman of the BoardFeb 11Sale325.1011,4753,730,523103,275Feb 12 04:15 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Sale325.005,8191,891,1750Feb 12 04:15 PM
GILMAN ALFRED GDirectorJan 14Option Exercise18.615,00093,0505,000Jan 14 05:25 PM
McCorkle Douglas SVP Controller and Asst TreasurJan 14Sale290.004,0001,160,0000Jan 14 05:26 PM
GILMAN ALFRED GDirectorJan 14Sale300.005,0001,500,0000Jan 14 05:25 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale274.7720,6685,678,96525,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise30.6348,0001,470,24073,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 24Option Exercise21.254,70599,98125,447Dec 26 01:26 PM
Powchik PeterSVP Clinical Development & RegDec 20Sale271.0913336,05520,742Dec 20 05:54 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 19Option Exercise21.254,70599,9811,068,343Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 18Option Exercise21.252956,26921,037Dec 20 05:54 PM
STAHL NEILSVP Research and Development SDec 18Option Exercise21.254,70599,98124,391Dec 19 09:49 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 18Option Exercise21.254,70599,98163,102Dec 19 09:49 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise21.254,70599,98115,441Dec 19 09:48 PM
Terifay Robert JSVP CommercialDec 18Option Exercise21.254,70599,98120,029Dec 19 09:48 PM
Powchik PeterSVP Clinical Development & RegDec 18Sale270.209,0002,431,80020,742Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 17Sale270.0082,16029,742Dec 17 04:16 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise107.1430,6253,281,05638,503Dec 17 04:16 PM
YANCOPOULOS GEORGEPres Regeneron LabsDec 12Option Exercise260.449,5992,499,9641,115,994Dec 13 04:29 PM
VAGELOS P ROYChairman of the BoardDec 02Sale296.119528,1302,257Dec 04 07:34 PM
SING GEORGE LDirectorNov 26Option Exercise15.0110,000150,100122,772Nov 27 04:22 PM
SING GEORGE LDirectorNov 26Sale295.0010,0002,950,000112,772Nov 27 04:22 PM
GOLDSTEIN JOSEPH LDirectorNov 06Sale300.741,000300,7403,000Nov 06 04:17 PM